Preparing for a novel era in CV prevention: Where do PCSK9 inhibitors fit in lipid management? - PACE-CME

Preparing for a novel era in CV prevention Where do PCSK inhibitors fit in lipid management

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Recommended

Extra work of checking device data weekly does not translate into benefit for HF patient
Extra work of checking device data weekly does not translate into benefit for HF patient
ESC 2016
Extra work of checking device data weekly does not translate into benefit for HF patient
- Martin Cowie, MD
Heart Failure news from ESC 2016 at a glance
Heart Failure news from ESC 2016 at a glance
ESC 2016
Heart Failure news from ESC 2016 at a glance
- Prof. Mariell Jessup
Iron deficiency in the new HF guidelines
Iron deficiency in the new HF guidelines
ESC 2016
Iron deficiency in the new HF guidelines
- Peter van der Meer, MD
What can new glucose-lowering SGLT2-inhibitors add to CV risk management in diabetes?
What can new glucose-lowering SGLT2-inhibitors add to CV risk management in diabetes?
CSI 2016 ESC
What can new glucose-lowering SGLT2-inhibitors add to CV risk management in diabetes?
- Prof. Silvio E Inzucchi